Zhejiang fritillary

Zhejiang Fritillary (Fritillaria thunbergii Miq.): A Comprehensive Reference

1. Identity, Nomenclature, and Natural Source

Fritillariae Thunbergii Bulbus (FTB) is also known as Zhe bei mu or Xiang bei mu in Chinese, Setsubaimo in Japanese, and Jeolpaemo in Korean. In English, the plant is most commonly called Zhejiang fritillary, Thunberg fritillary, or Chekiang fritillary. The accepted botanical name is Fritillaria thunbergii Miq., first formally described by the Dutch botanist Friedrich Anton Wilhelm Miquel (1811–1871).

Fritillariae Thunbergii belongs to the Fritillariae (Liliaceae) family and FTB has been widely used as an antitussive herb for thousands of years in China. Fritillariae Thunbergii is widely cultivated in the south-eastern coastal, south-central and eastern areas of China, such as Zhejiang, Jiangsu, Anhui, and Hunan provinces.

Various Fritillaria species have been recorded in the Pharmacopoeia of the People's Republic of China (1995, 2000, 2005, 2010, and 2015 editions) and are widely distributed across China. More than 40 species have been used as plant sources for a variety of Beimu herbs. Among all the species, Zhe-Beimu (F. thunbergii Miq.), Chuan-BeiMu (F. cirrhosa D. Don), Hubei-Beimu (F. hupehensis Hsiao and K. C. Hsia), and Yi-Beimu (F. pallidiflora Schrenk) are the most common in clinical usage and for herbal medicine development.

The medicinally used part of the plant is the dried bulb, designated in Chinese pharmaceutical nomenclature as Fritillariae Thunbergii Bulbus (FTB). The flower (Fritillariae Thunbergii Flos, FTF) has also been investigated pharmacologically. Fritillariae Thunbergii Flos (FTF), included in the Chinese Pharmacopoeia (1977 Edition), is a Chinese medicinal herb traditionally used to treat bronchitis. According to the Chinese Pharmacopoeia, the total peimine (C₂₇H₄₅NO₃) and peiminine (C₂₇H₄₃NO₃) content of the dry product of FTB should be above 0.08%.

Common Names and Synonyms

• Chinese: 浙贝母 (Zhè bèi mǔ), 象贝 (Xiàng bèi), 象贝母 (Xiàng bèi mǔ)
• Japanese: Setsubaimo (節貝母)
• Korean: Jeolpaemo (절패모)
• English: Zhejiang fritillary, Thunberg fritillary, Chekiang fritillary
• Pharmaceutical: Bulbus Fritillariae Thunbergii; Fritillariae Thunbergii Bulbus (FTB)

The name "Xiang Bei" (象贝, Elephant Shell Mother) derives from Xiangshan county in Ningbo, Zhejiang, its original production area.

Common Preparations and Forms

Because the raw bulb is toxic, all medicinal forms are processed. Good quality processed powder is white and has a fine consistency. Small, white, lobed bulbs that have been boiled or steamed and dried are also available. Prepared forms encountered in clinical and commercial use include:

• Decoction pieces (yinpian): dried, sliced bulbs prepared into water decoctions
• Fine powder (ground processed bulb)
• Concentrated granules (spray-dried extract powders)
• Pills and tablets, typically as a component of multi-herb formulas
• Pills in equivalent doses are also available, and the herb may also be applied externally as either a powder or cream.

Beimu (Fritillaria Bulbus), which is derived from various Fritillaria plants, has been used as an antitussive herb for more than 2000 years in TCM. This anti-cough remedy is extensively used because of its non-addictive property and fewer side effects compared to commercially available morphine-like, anti-cough medicines which contain codeine.

2. Traditional and Historical Use

Earliest Records and Pre-Ming Undifferentiated Use

According to historical materials, before the Ming dynasty, Fritillariae Thunbergii Bulbus (known as zhebeimu, FTB) and other Fritillaria Bulbs were collectively named "Beimu." Beimu was first recorded in "Shen Nong Ben Cao Jing," the earliest monograph of TCM, and has been described as a cough medicine with good throat-clearing and detoxification effects.

Prior to the Ming dynasty, all classical texts simply referred to "Bei Mu" without distinguishing between Chuan Bei Mu (Sichuan Fritillaria) and Zhe Bei Mu (Zhejiang Fritillaria). The Xin Xiu Ben Cao (Newly Revised Materia Medica, Tang dynasty) noted that the best Bei Mu came from Runzhou (modern-day Zhenjiang, Jiangsu), suggesting that the ancient herb included what we now call Zhe Bei Mu.

Differentiation from Sichuan Fritillary: Ming Dynasty

The formal separation began in the Ming dynasty. Zhang Jiebin's Ben Cao Zheng (Orthodox Materia Medica, 1624) was the first text to discuss "Tu Bei Mu" (Zhe Bei Mu's early name) as a distinct entry separate from Chuan Bei Mu.

In the Ming dynasty, another medical monograph called "Ben Cao Hui Yan" (Nizhumo, 1624, Ming dynasty) summarized the differences between Fritillariae Cirrhosae Bulbus (FCB) and Fritillariae Thunbergii Bulbus (FTB), indicating that FCB tended to moisten the lung, eliminate phlegm, and relieve cough and asthma, while FTB tended to clear heat and detoxify.

Qing Dynasty Elaboration

Five classic books from the Qing dynasty and Republic of China period — Ben Cao Zheng Yao (Li Zhongzi, 1673), Ben Jing Feng Yuan (Zhang Lu, 1695), Ben Cao Gang Mu Shi Yi (Zhao Xuemin, 1765), Ben Cao Bian Du (Zhang Bingcheng, 1887), and Ben Cao Zheng Yi (Zhang Shanlei, 1920) — specified that the unique actions of FTB were to clear the Lung and calm the Liver, disperse the Lung-Qi to relieve depression, and clear the Heart and reduce heat, properties not found in other Fritillariae species such as Fritillariae Cirrhosae Bulbus (Chuan bei mu) and Bolbostemmatis Rhizoma (Tu Bei Mu).

Traditional TCM Classification and Indications

FTB is a significant traditional Chinese herb with bitter and cold properties, entering the Lung and Heart channels. Historical records indicate that it acts to clear heat, resolve phlegm, relieve cough, remove toxicity, and disperse abscesses and nodules.

Chekiang Fritillary has been historically used to treat various types of cough, particularly those classified as "damp" or "phlegm-heat" coughs. According to TCM theory, Zhe Bei Mu is categorized as an herb that "clears heat and transforms phlegm," making it suitable for coughs with symptoms such as thick, yellow sputum, a sensation of chest congestion, and a greasy tongue coating — signs associated with dampness and heat in the lungs.

The bulbs are medicinally important in treating cough, inflammation, gastric ulcers, hypertension, diarrhea, and bronchitis.

Use in Compound Formulas

FTB is generally prescribed as one of the ingredients of herbal formulas, such as Danggui Beimu Kushen Wan (Chinese Angelica, Fritillaria and Flavescent Sophora Pill; DBKW) in traditional and contemporary clinical practice. Additional classical formulas in which FTB features include Hai Zao Yu Hu Tang (Sargassum Decoction for the Jade Flask), which is traditionally categorized among formulas that transform phlegm and dissipate nodules, and Xiao Luo Wan (Reduce Scrofula Pill). Today, some formulas are continuously used by practitioners in evidence-based Chinese medicine clinical practice, such as DBKW and Guang Bi Shu Zhan Tang (Throat Tuberculosis Decoction).

Cross-Cultural Historical Use

Bulbus Fritillariae (Bei-Mu), derived from various Fritillaria species, holds a prominent position in traditional medicine systems across China, Korea, and Japan. For centuries, it has been valued primarily for its potent antitussive and expectorant properties in treating respiratory ailments such as bronchitis and asthma.

Fritillariae thunbergii Bulbus (FTB) has a long history as a traditional herbal medicine used as an antitussive and expectorant in several Asian countries, including Korea, China, and Japan.

3. Key Chemical Constituents

Overall Phytochemical Profile

A systematic review identified 134 chemical constituents in FTB, including 26 alkaloids, 29 compounds found in essential oils, 13 diterpenoids, two carbohydrates, two sterols, 18 amino acids, six nucleosides, four nucleobases, four fatty acids, three lignans, and 27 elements.

F. thunbergii and its bulbs mainly constitute alkaloids, essential oils, diterpenoids, carbohydrates, sterols, amino acids, nucleosides, fatty acids, and lignans.

Alkaloids: Primary Bioactive Class

Thirteen pharmacological effects of FTB have been identified, and these pharmacological activities may be mainly attributed to the alkaloids in FTB.

Pharmacological analyses of various extracts and pure compounds isolated from different Fritillaria species, including F. thunbergii, demonstrate that peimine and peiminine are the major cevanine type of isosteroidal alkaloids with characteristic hexacyclic benzo(7,8)fluoreno(2,1-b)quinolizine nucleus. These exist in different Fritillaria species and were the primary active ingredients responsible for antitussive activity.

Bulbus Fritillariae thunbergii contains peimine, peiminine, and peimisine as its principal alkaloids.

In all parts of F. thunbergii, 37 alkaloids have been simultaneously analyzed, including peimine, peimisine, peiminine, ebeiedinone/puqiedinone, ebeiedine/puqiedine, and peimisine-N-oxide, as well as zhebeininoside.

Additional alkaloids identified in F. thunbergii include sipeimine, propeimine, peimidine, peimiphine, peimitidine, and isoverticine, and the glycoside peimisnoside. The steroidal alkaloid verticinone (also present in some preparations) is sometimes used interchangeably with the term "imperialine" across different Fritillaria species; its distinct presence in FTB versus closely related species depends on the specific chemotype.

Non-Alkaloid Constituents

Fritillaria always contains saponins, alkaloids, amino acids, flavones, and polysaccharides. Fritillaria polysaccharides have a variety of biological activities, and their anti-inflammatory and antiaging activities are new areas of study.

Steroidal alkaloids are nitrogenous secondary metabolites derived from natural plants including Fritillariae, and are recognized as potential biological effectors with anticancer, anticholinergic, antimicrobial, and anti-inflammatory activities.

4. Established Mechanisms of Action

Antitussive and Tracheobronchial Relaxation

Two studies investigated the tracheobronchial relaxation activity of FTB extract in isolated bronchial and tracheal rings of rats. Peimine (A1), peiminine (A2), ebeiedine (A5), and puqietinone (A13) extracted from FTB relaxed the tracheobronchi in vitro with pD2 values of 6.9 ± 0.1, 6.4 ± 0.12, 6.3 ± 0.09, and 5.7 ± 0.07 (bronchi), respectively, and 6.9 ± 0.12, 6.8 ± 0.18, 6.5 ± 0.08, and 6.0 ± 0.16 (tracheas).

The mechanism of tracheobronchial relaxation activity of FTB may be related to activation of Ca²⁺-activated K⁺ channels, since peimine (A1), peiminine (A2), and ebeiedine (A5) inhibited Ca²⁺-influx.

Anti-Inflammatory Mechanisms

Experiments show that peimine inhibits the production of LPS-induced inflammatory cytokines by blocking the MAPKs and NF-κB signaling pathways.

Peiminine can substantially lessen LPS-induced expression of many pro-inflammatory cytokines, including TNF-α, IL-6, cyclooxygenase-2, and inducible nitric oxide synthase, by suppressing the phosphorylation of protein kinase B (AKT) and NF-κB p65.

After treatment with each of the four major alkaloids (peimine, peimisine, peiminine, and sipeimine) at non-toxic concentrations (25 μg/mL), the mRNA expression levels of pro-inflammatory cytokines in LPS-stimulated RAW 264.7 cells were reduced.

Anticancer Mechanisms

FTB-derived peiminine inhibits cancer cell growth and movement and induces apoptosis by increasing the intracellular concentration of Ca²⁺ and phosphorylation induction of calcium/calmodulin-dependent protein kinase II (CaMKII) and JNK.

Furthermore, peiminine mediates cell cycle arrest by inhibiting Akt/glycogen synthase kinase 3 beta (GSK3β) and AMP-activated protein kinase (AMPK)/autophagy-activating kinase (ULK1) signaling, which leads to reduced autophagic flux.

Alkaloids and nucleosides in FTB significantly restricted the efflux activity of P-glycoprotein (P-gp) in a dosage-dependent manner. Peimine (A1) and peiminine (A2) were identified as the reversal agents in FTB that reversed the multidrug resistance of adriamycin or paclitaxel in MCF7/A cells. The reversal fold (RF) of peimine plus adriamycin or paclitaxel and peiminine plus adriamycin or paclitaxel was 8.17, 4.57, 3.30, and 3.73 respectively after 48-hour treatment.

Network pharmacological analysis identified PIK3CG, SRC, JAK3, AKT2, and PRKCA as key potential targets of peiminine in lung cancer treatment. Molecular docking results demonstrated strong binding affinities between peiminine and PIK3CG, SRC, and JAK3.

The possible mechanism of Fritillariae Thunbergii Flos in lung cancer treatment involves inflammatory response, angiogenesis, apoptotic process, and cell proliferation and migration. PIK3CG, Bcl-2, eNOS, VEGF, p-STAT3, and STAT3 genes in tumor-bearing mice may be key targets of Fritillariae Thunbergii Flos in lung cancer treatment.

Antihypertensive and Cardiovascular Mechanisms

Verticinone, a constituent of F. thunbergii, inhibits the activity of angiotensin converting enzyme, suggesting that F. thunbergii also has an antihypertensive impact.

Hypoglycemic Mechanisms

In vitro experiments have shown that FTB-derived verticinone has a hypoglycemic effect mediated by increased insulin secretion, glucose uptake, and inhibition of carbohydrate hydrolase activity.

Pain Suppression

The FTB alkaloid peimine was found to inhibit the Nav1.7 ion channel (present in the peripheral nervous system), providing a cellular basis for its pain-suppressing properties.

5. Scientific Evidence by Area of Use

5.1 Respiratory System: Antitussive and Expectorant Effects

Evidence level: Pre-clinical (animal and in vitro); substantial traditional precedent; limited controlled human trials.

Thirteen pharmacological effects of FTB have been identified, including tracheobronchial relaxation, antitussive, and expectorant effects. The antitussive evidence base for FTB rests primarily on animal models, in vitro bronchial ring assays, and centuries of empirical clinical application. Direct, randomized controlled trials in humans specifically isolating FTB as a mono-intervention are lacking in the peer-reviewed English literature; existing studies most commonly assess FTB as part of multi-component TCM formulations.

Fritillaria thunbergii preparations are used in traditional Chinese medicines that are often administered in clinical settings and have notable effects on cough, bronchitis, and pneumonia. Fritillariae thunbergii Bulbus (FTB) is a traditional Chinese medicine with widely recognized expectorant, antitussive, antiasthmatic, antiviral, and anticancer properties.

The mechanistic rationale for antitussive action is supported by in vitro evidence showing that the principal alkaloids relax bronchial and tracheal smooth muscle by activating Ca²⁺-activated potassium channels, as described in Section 4 above. The overall antitussive and expectorant evidence is preliminary-to-moderate by modern standards, robust by traditional use standards, but insufficient as isolated clinical proof of efficacy.

5.2 Anti-Inflammatory Activity

Evidence level: In vitro and animal models; mechanistically coherent; no controlled human clinical trials on FTB alone.

Multiple cell-based studies have demonstrated that the major FTB alkaloids peimine and peiminine suppress pro-inflammatory cytokine production via NF-κB and MAPK pathway inhibition. The primary chemical constituents exhibiting anti-inflammatory effects are peimine and peiminine, which are common to both F. cirrhosa and F. thunbergii. These mechanisms have been validated in macrophage cell lines and, to a lesser extent, in rodent models of inflammation. Controlled human evidence is absent at this time, and the in vitro results cannot be directly extrapolated to human clinical outcomes without further study.

5.3 Anticancer Activity

Evidence level: In vitro and animal; exploratory only; no human clinical trials.

Fritillin A obtained from FTB inhibited the proliferation and stimulated apoptosis of KG-1a human acute myeloid leukemia cells in vitro.

Direct anti-cancer activity was also detected by in vitro and in vivo studies. Researchers found that the FTB aqueous extract (75 mg/mL) inhibited human lung adenocarcinoma parental cells LM2 with dosage dependence, and the apoptosis rate was increased over time (24 h: 5.7 ± 0.91%; 48 h: 11.7 ± 1.07%).

In recent years, Thunberg Fritillary Bulb has been extensively used for the treatment of drug-resistant leukemia and other cancers with reported good outcomes. However, these reports are from Chinese clinical databases and are not standardized randomized controlled trials. The multidrug resistance-reversing capacity of FTB alkaloids (via P-gp inhibition, as described in Section 4) is pharmacologically relevant but has not been validated in controlled human oncology trials. All anticancer evidence for FTB remains exploratory.

5.4 Antiviral Activity (Influenza)

Evidence level: In vitro, in ovo, and animal (murine) models; no human clinical trials.

The bulbs of Fritillaria thunbergii (FT) belonging to the lily family have been traditionally used as expectorants for controlling airway inflammatory diseases and treatment of coughs, bronchitis, pneumonia, and fever-based illnesses. Researchers examined the hypothesis that FT should not only reduce the respiratory symptoms associated with influenza but also inhibit influenza virus activity. The therapeutic effects of FT against influenza A were compared to those of the conventional anti-influenza drug oseltamivir in vitro, in ovo, and in vivo.

In ovo results showed that FT extract exerts an antiviral effect against H1N1 in embryonated eggs without inducing cytotoxicity at a high concentration of 150 mg/kg. Collective results suggest that FT extracts exert antiviral effects against influenza H1N1 virus without inducing toxicity in vitro, in ovo, or in vivo, thereby supporting the potential utility of FT extract as a novel candidate therapeutic drug or supplement against influenza.

The bulbs of Fritillariae thunbergii (FT) have been traditionally used to control airway inflammatory diseases, such as bronchitis and pneumonia. To elucidate active compounds, targets, and underlying mechanisms of FT for the treatment of influenza-induced inflammation, systems biology (network pharmacology) has been employed. Antiviral evidence is promising but remains at the pre-clinical stage; no controlled human trials exist.

5.5 Gastric and Gastrointestinal Effects

Evidence level: Animal and in vitro; no controlled human trials for FTB as a mono-intervention.

Identified pharmacological effects of FTB include antiulcer and anti-diarrhea activity. These effects have been demonstrated in animal models but have not been systematically evaluated in human subjects independent of multi-herb formulations. Traditional use of FTB in treating gastric ulcers and diarrhea is well-documented across historical sources.

5.6 Cardiovascular and Blood Rheology

Evidence level: Animal and in vitro; limited mechanistic evidence only.

Pharmacological studies indicate that F. thunbergii may aid in the regulation of blood rheology. Verticinone inhibits the activity of angiotensin-converting enzyme, suggesting an antihypertensive impact. These findings are derived from animal models and enzyme-inhibition assays. No human clinical data on cardiovascular outcomes for FTB are available in the reviewed literature.

5.7 Neuroprotective and Pain-Suppressing Effects

Evidence level: In vitro and animal; mechanistically interesting; no human evidence.

The FTB alkaloid peimine was found to be a potential pain suppressor, as it inhibits the Nav1.7 ion channel present in the peripheral nervous system. Neuroprotective effects have been described in cell-culture systems but have not been evaluated in human trials. This remains one of the least-studied areas of FTB research and is highly preliminary.

5.8 Anti-Thyroid Effects

Evidence level: Animal and in vitro; preliminary only.

Anti-thyroid activity is among the thirteen pharmacological effects identified for FTB in the systematic review literature. Mechanistic details for this effect are incompletely characterized, and no human clinical data exist.

6. Body Systems and Health Areas of Association

Based on the published pharmacological literature, the body systems with which Zhejiang fritillary is most strongly associated are:

• Respiratory system: Antitussive, expectorant, tracheobronchial relaxation, anti-asthmatic
• Immune/inflammatory system: Anti-inflammatory via NF-κB and MAPK inhibition
• Oncology: Antiproliferative, pro-apoptotic, multidrug resistance reversal in vitro
• Cardiovascular system: ACE inhibition, blood rheology regulation, mild antihypertensive
• Gastrointestinal system: Anti-ulcer, anti-diarrheal
• Neurological system: Pain suppression (Nav1.7 inhibition), neuroprotection
• Endocrine system: Anti-thyroid activity, preliminary hypoglycemic effects
• Antimicrobial/antiviral: Anti-influenza (H1N1) activity in pre-clinical models

Pharmacological studies demonstrate that F. thunbergii and its bulbs display a wide range of bioactivities, including anti-inflammatory, anticancer, antitussive, expectorant, anti-ulcer, antimicrobial, antioxidant, anti-thyroid, regulation of blood rheology, anti-diarrhea, neuroprotection, and analgesic effects.

7. Dosage Forms and Reported Dosages

The dosages below are reported exclusively as stated in referenced sources and reflect traditional clinical practice and reported research parameters, not recommendations.

The standard dose ranges from 3–12 grams daily as a decoction (strong tea) or 1–1.5 grams as powder.

Reference texts used in TCM clinical practice report a wider range: 10–20 grams in decoction (per Chen's reference) or 4.5–9 grams in decoction (per Bensky's reference).

In pharmacological research contexts, relevant dosage parameters that have been used include:

• An aqueous extract concentration of 75 mg/mL was used in the in vitro lung adenocarcinoma cell study.
• A dose of 150 mg/kg was used in in ovo antiviral testing.
• The four major alkaloids showed no toxicity at concentrations of 0–25 μg/mL in RAW 264.7 macrophage cells.

Regarding preparation quality standards, the Chinese Pharmacopoeia specifies that the total peimine and peiminine content of the dry product of FTB should be above 0.08%.

Preparation of bulbs is an important quality consideration. Traditional processing includes boiling or steaming followed by drying. Research has examined the impact of different processing conditions: HPLC-ELSD analysis showed that, with organic fertilizer application, the content of peimine and peiminine in cultivated F. thunbergii reached 0.0603% and 0.0502%, respectively. There are also documented concerns that sulfur-fumigation — a post-harvest processing method sometimes used to whiten and preserve the bulb — can destructively alter the inherent chemical quality of Zhebeimu.

8. Safety Considerations and Interactions

Processing Requirement: Raw Bulb Toxicity

Because the raw bulb is toxic, all medicinal forms are processed. Raw, unprocessed fritillary bulb should not be consumed.

Acute and Sub-Chronic Toxicity

In Chinese medical clinical practice, Thunberg Fritillary Bulb is used for the treatment of a variety of conditions, such as cough, bronchitis, inflammation, hypertension, gastric ulcer, diarrhea, bacterial infection, and tumor. Formal toxicological data in humans are limited. Pre-clinical acute toxicity testing in mice showed that acute toxicity increased progressively as the dose increased from 14.3 to 80.0 mg/kg. The four major alkaloids — peimine, peimisine, peiminine, and sipeimine — showed no toxicity at concentrations of 0–25 μg/mL in RAW 264.7 cells.

The "Eighteen Antagonisms" (Shi Ba Fan): Incompatibility with Aconite

The traditional Chinese medicine theory of "eighteen incompatible medicaments" refers to the incompatibility of Chinese herbs, indicating that pairs of herbs which are mutually incompatible should not be used simultaneously. Bulbus fritillariae and Radix aconiti praeparata are one incompatible herbal pair as recorded in "eighteen incompatible medicaments."

A mechanistic explanation for this classical prohibition has been partially provided by modern pharmacology: when Radix aconiti praeparata was combined with Bulbus fritillariae, the toxic ingredient benzoylmesaconine in Radix aconiti praeparata displayed higher intestinal permeability. Bulbus fritillariae thunbergii inhibited both the P-gp function and expression (whereas Bulbus fritillariae cirrhosae inhibited function only). Alkaloids including peimine, peimisine, and imperialine were the active ingredients for inhibiting P-gp activity, and benzoylmesaconine in Radix aconiti praeparata was the substrate of P-gp.

The practical consequence of this interaction is that FTB can increase the intestinal absorption of toxic aconitine-type alkaloids from aconite root preparations, potentially increasing their toxicity. An animal study tested this combination in a disease model: at the early stage of pulmonary hypertension, Fuzi and Beimu combination significantly improved lung function and reduced pulmonary histopathology; however, as the disease progressed, when the combination was used at the late stage, right ventricular chamber dilation was histologically apparent and myocardial apoptosis was significantly increased compared with each drug alone.

TCM Contraindications

According to TCM clinical sources, FTB is considered contraindicated in cough patterns arising from cold-phlegm or Yin-deficient dry cough, for which Chuan Bei Mu (F. cirrhosa) is considered more appropriate due to its different energetic properties. FTB should not be used with Wu Tou, and should not be used in cases of Cold or Damp.

P-glycoprotein Inhibition and Drug Interaction Potential

Bulbus fritillariae thunbergii inhibits both the P-gp function and expression; alkaloids including peimine, peimisine, and imperialine are the active ingredients for inhibiting P-gp activity. Since P-glycoprotein (P-gp, ABCB1) is a major efflux transporter affecting the bioavailability and disposition of numerous pharmaceutical drugs, the P-gp-inhibiting activity of FTB alkaloids raises theoretical concerns about interactions with co-administered drugs that are P-gp substrates. This pharmacokinetic interaction has been documented in animal systems but has not been evaluated in human pharmacokinetic studies. It represents an important area for caution and further investigation, particularly in patients taking medications with narrow therapeutic windows that are known P-gp substrates.

Pesticide and Heavy Metal Contamination Risks

F. thunbergii (Zhe Beimu) is widely cultivated in China's Zhejiang province, and pesticides and heavy metals are two major factors affecting its quality and safety. A total of 106 F. thunbergii samples from six main production areas were analyzed for 76 pesticides and four heavy metals (As, Cd, Hg, and Pb). This study highlights that quality control and provenance verification are important practical considerations for commercially available FTB preparations.

Sulfur Fumigation Processing Concerns

Sulfur fumigation is a traditional preservation method that has been shown to significantly alter the phytochemical profile of FTB. Research using chromatographic fingerprinting has documented that this processing method can degrade the inherent quality of Zhebeimu, with potential consequences for both efficacy and safety. Preparation method and post-harvest handling are therefore meaningful variables when evaluating the quality of any FTB product.

Overall Evidence Limitations for Safety

Systematic human safety data for FTB as an isolated supplement are not available. The existing toxicological literature is dominated by animal and cell-culture studies. The long history of use in TCM clinical practice — predominantly in multi-herb formulations at traditional decoction doses — provides a substantial empirical safety record, but this does not substitute for controlled human safety trials. No regulatory authority (e.g., FDA, EMA, EFSA) has issued a formal assessment monograph specifically for Fritillaria thunbergii as a dietary supplement.

References

• Deng et al. (2019). Fritillariae Thunbergii Bulbus: Traditional Uses, Phytochemistry, Pharmacodynamics, Pharmacokinetics and Toxicity. International Journal of Molecular Sciences, 20(7), 1667. PMC6479889.
• Deng et al. (2019). Fritillariae Thunbergii Bulbus: Traditional Uses, Phytochemistry, Pharmacodynamics, Pharmacokinetics and Toxicity. MDPI International Journal of Molecular Sciences.
• Nile et al. (2021). Fritillaria thunbergii Miq. (Zhe Beimu): A review on its traditional uses, phytochemical profile and pharmacological properties. Food and Chemical Toxicology. ScienceDirect.
• Wu et al. (2022). Efficacy, chemical composition, and pharmacological effects of herbal drugs derived from Fritillaria cirrhosa D. Don and Fritillaria thunbergii Miq. Frontiers in Pharmacology.
• Wu et al. (2022). Efficacy, chemical composition, and pharmacological effects of herbal drugs derived from Fritillaria cirrhosa D. Don and Fritillaria thunbergii Miq. PMC9748432.
• Kim et al. (2022). Antiviral Activity of Fritillaria thunbergii Extract against Human Influenza Virus H1N1 (PR8) In Vitro, In Ovo and In Vivo. PMC9728163.
• Kim et al. (2020). Identifying Active Compounds and Targets of Fritillariae thunbergii against Influenza-Associated Inflammation by Network Pharmacology Analysis and Molecular Docking. PMC7504253.
• Study on pharmacokinetics of steroidal alkaloids from Fritillariae thunbergii Bulbus in colitis rats. PMC11357484.
• Liu et al. (2021). Studies on the Incompatibility between Bulbus fritillariae and Radix aconiti praeparata Based on the P-gp. Evidence-Based Complementary and Alternative Medicine. PMC8510812.
• Scientific Reports (2016). cAMP-PKA-CaMKII signaling pathway is involved in aggravated cardiotoxicity during Fuzi and Beimu Combination Treatment of Experimental Pulmonary Hypertension.
• Systematic Review on Traditional Uses, Sources, Phytochemistry, Pharmacology, Pharmacokinetics, and Toxicity of Fritillariae Cirrhosae Bulbus. PMC7676930.
• Peiminine acts as a chemosensitizer to potentiate oxaliplatin efficacy against gastric cancer. ScienceDirect (2025).
• Yang et al. (2025). A Multi-Level Study on the Anti-Lung Cancer Mechanism of Peiminine, a Key Component of Fritillaria ussuriensis Maxim. PMC12027391.
• Acute and sub-chronic toxicity studies of the extract of Thunberg Fritillary Bulb. PubMed 24486111.
• Identification of alkaloids and flavonoids in all parts of Fritillaria thunbergii using LC-LTQ-Orbitrap MSn. PubMed 28901111.
• Botanical characterization, phytochemistry, biosynthesis, pharmacology, clinical application, and breeding techniques of Fritillaria unibracteata. PMC11317884.
• Peimine, a main active ingredient of Fritillaria, exhibits anti-inflammatory and pain suppression properties at the cellular level. ScienceDirect.
• Encyclopedia.com. Fritillaria entry.